Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.

ABSTRACT:

Background

Acute myeloid leukemia (AML) is a heterogeneous disease that frequently relapses after standard chemotherapy. Therefore, there is a need for the development of novel chemotherapeutic agents that could treat AML effectively. Radotinib, an oral BCR-ABL tyrosine kinase inhibitor, was developed as a drug for the treatment of chronic myeloid leukemia. Previously, we reported that radotinib exerts increased cytotoxic effects towards AML cells. However, little is known about the effects of combining radotinib with Ara-C, a conventional chemotherapeutic agent for AML, with respect to cell death in AML cells. Therefore, we investigated combination effects of radotinib and Ara-C on AML in this study.

Methods

Synergistic anti-cancer effects of radotinib and Ara-C in AML cell

SUBMITTER: Heo SK 

PROVIDER: S-EPMC7718665 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature